Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61370 | 1.00 | ALOX15 (0.42) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| SCHEMBL6026424 | 1.00 | ALOX15 (0.42) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| SCHEMBL7162435 | 0.98 | ALOX15 (0.41) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| Water SCHEMBL6933673 | 0.98 | ALOX15 (0.41) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| Water SCHEMBL8680771 | 0.98 | ALOX15 (0.41) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| SCHEMBL7162439 | 0.98 | ALOX15 (0.41) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| SCHEMBL27782981 | 0.94 | CTSS (0.39) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| SCHEMBL27782979 | 0.94 | CTSS (0.39) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| D-Alanine SCHEMBL7432397 | 0.93 | ALDH1A1 (0.40) | ALOX15KDM4EMAPTTHRBNFKB1 | |
| SCHEMBL11133973 | 0.92 | TNF (0.37) | ALOX15KDM4EMAPTTHRBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1742 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260026495-A1 | STABLE PLASMIN COMPOSITIONS FOR ORGAN PRESERVATION AND RECONDITIONING | GRIFOLS WORLDWIDE OPERATIONS LTD (IE) | 2026-01-29 | — | — | US | claimed |
| WO-2025245279-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USE THEREFORE IN TREATMENT OF ADDICTION AND/OR PAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245292-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT LOSS | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2025123059-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR TREATING SUBSTANCE USE DISORDERS | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025123051-A1 | NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-06-12 | — | — | WO | claimed |
| US-5925317-A | Dual neutralization system for iodine treatment of contact lenses | BAUSCH & LOMB INCORPORATED (US) | 1999-07-20 | — | — | US | claimed |
| EP-0885019-A1 | DUAL NEUTRALIZATION SYSTEM FOR IODINE TREATMENT OF CONTACT LENSES | BAUSCH & LOMB INCORPORATED (US) | 1998-12-23 | — | — | EP | claimed |
| EP-0433112-B1 | Modified gangliosides and the functional derivatives thereof | FIDIA SPA (IT) | 1998-10-28 | — | — | EP | claimed |
| WO-1997026923-A1 | DUAL NEUTRALIZATION SYSTEM FOR IODINE TREATMENT OF CONTACT LENSES | BAUSCH & LOMB INCORPORATED (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0620293-B1 | Composition for treating copper or copper alloys | MEC CO LTD (JP) | 1997-01-15 | — | — | EP | claimed |
| WO-1996006639-A2 | NOVEL DRUGS CONTAINING CHELATE-FORMING AGENTS | MEDICO PHARMA VERTRIEBS GMBH (DE) | 1996-03-07 | — | — | WO | claimed |
| US-5439783-A | Consists of cupric complex of azole compound, an organic acid, a difficultly volatile complexing agent and water; used for surface treatment by oxidative etching | MEC CO., LTD. (JP) | 1995-08-08 | — | — | US | claimed |
| EP-0620293-A1 | Composition for treating copper or copper alloys | MEC CO., Ltd. (JP) | 1994-10-19 | — | — | EP | claimed |
| WO-1993002689-A1 | SYNTHETIC RIBONUCLEASES AND METHODS FOR PREPARING AND USING SAME | UNIVERSITY OF MEDICINE & DENTISTRY (US) | 1993-02-18 | — | — | WO | claimed |
| EP-0433112-A1 | Modified gangliosides and the functional derivatives thereof | FIDIA S.p.A. (IT) | 1991-06-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260026495-A1 | STABLE PLASMIN COMPOSITIONS FOR ORGAN PRESERVATION AND RECONDITIONING | PLG, PLPBP, F2 | ALOX15 3432/4885KDM4E 2283/4885MAPT 2186/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | ALOX15 2075/4885KDM4E 4749/4885MAPT 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.